Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 15/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 15/20 | 0.36 |
| ▸ | SLC2A4 | P14672 | 15/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 5/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10083881 | 0.94 | SLC2A1 (0.35) | SLC2A1SLC2A3SLC2A4SLC2A2CACNA1H | |
| SCHEMBL13085225 | 0.92 | SLC2A1 (0.37) | SLC2A1SLC2A3SLC2A4SLC2A2CACNA1H | |
| SCHEMBL10075536 | 0.90 | SLC2A1 (0.37) | SLC2A1SLC2A3SLC2A4SLC2A2CACNA1H | |
| SCHEMBL13085455 | 0.90 | L3MBTL1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2CACNA1H | |
| SCHEMBL13090538 | 0.90 | CNR1 (0.33) | SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL13085456 | 0.90 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2CACNA1H | |
| SCHEMBL29454974 | 0.89 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2CACNA1H | |
| SCHEMBL10083882 | 0.89 | SLC2A1 (0.33) | SLC2A1SLC2A3SLC2A4SLC2A2CETP | |
| SCHEMBL29454972 | 0.89 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2CACNA1H | |
| SCHEMBL798149 | 0.89 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324390-B2 | Tetrazole-substituted anthranilamides as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324390-B2 | Tetrazole-substituted anthranilamides as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20100256195-A1 | Tetrazole-substituted anthranilamides as pesticides | BAYER CROPSCIENCE AG (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256195-A1 | Tetrazole-substituted anthranilamides as pesticides | BAYER CROPSCIENCE AG (DE) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256195-A1 | Tetrazole-substituted anthranilamides as pesticides | ANTXR2, PNISR, H1-5 | SLC2A1 2324/4885SLC2A3 2023/4885SLC2A4 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.